PT  - JOURNAL ARTICLE
AU  - Ventriglia, Jole
AU  - Paciolla, Immacolata
AU  - Pisano, Carmela
AU  - Tambaro, Rosa
AU  - Cecere, Sabrina Chiara
AU  - Di Napoli, Marilena
AU  - Attademo, Laura
AU  - Arenare, Laura
AU  - Spina, Anna
AU  - Russo, Daniela
AU  - Califano, Daniela
AU  - Losito, Nunzia Simona
AU  - Setola, Sergio Venanzio
AU  - Franzese, Elisena
AU  - De Vita, Ferdinando
AU  - Orditura, Michele
AU  - Pignata, Sandro
TI  - Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy
AID  - 10.1136/ijgc-2020-001540
DP  - 2021 Jan 01
TA  - International Journal of Gynecologic Cancer
PG  - 110--113
VI  - 31
IP  - 1
4099  - http://ijgc.bmj.com/content/31/1/110.short
4100  - http://ijgc.bmj.com/content/31/1/110.full
SO  - Int J Gynecol Cancer2021 Jan 01; 31
AB  - Background Chemotherapy with carboplatin, paclitaxel, and bevacizumab is the standard therapy for patients with advanced stage ovarian cancer wild-type BRCA after primary surgery. The most frequent side effects of bevacizumab in this setting are hypertension, thrombosis, hemorrhage, and proteinuria, while arthralgia has been poorly described.Objective To examine the incidence, duration, and reversibility of arthralgia.Patients and methods A retrospective analysis was performed to describe the occurrence and outcome of arthralgia in 114 patients with advanced ovarian cancer, given first-line treatment with a combination of carboplatin, paclitaxel, and bevacizumab. Statistical analysis was performed to investigate a possible prognostic role of arthralgia, with progression-free survival as endpoint.Results 47 of 114 patients (41%) developed arthralgia during therapy. All patients had grade 1 or grade 2 arthralgia. Toxicity persisted after the end of bevacizumab in 17/47 patients (36%). Median progression-free survival for patients without arthralgia was 18 months (95% CI 14 to 24) compared with 29 months (95% CI 21 to not reached) for patients experiencing arthralgia (p=0.03). In order to avoid possible biases related to treatment duration, a multivariable Cox proportional hazards model including toxicity as a time dependent variable and age, stage, and residual disease after primary surgery was performed. In this model no variable showed a statistically significant association with progression-free survival.Conclusion A high incidence of arthralgia (41%) was found and although rogression-free survival was worse for those patients who developed arthralgia, this was not maintained on multivariate analysis. Guidelines for treatment of this adverse event are needed.